Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate CRISPR Therapeutics AG before investing.

In this article, we go over a few key elements for understanding CRISPR Therapeutics AG’s stock price such as:

• CRISPR Therapeutics AG’s current stock price and volume
• Why CRISPR Therapeutics AG’s stock price changed recently
• Upgrades and downgrades for CRSP from analysts
• CRSP’s stock price momentum as measured by its relative strength

About CRISPR Therapeutics AG (CRSP)

Before we jump into CRISPR Therapeutics AG’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Want to learn more about CRISPR Therapeutics AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about CRISPR Therapeutics AG.

CRISPR Therapeutics AG’s Stock Price as of Market Close

As of June 05, 2026, 4:00 PM, CST, CRISPR Therapeutics AG’s stock price was $51.840.

CRISPR Therapeutics AG is down 8.97% from its previous closing price of $56.950.

During the last market session, CRISPR Therapeutics AG’s stock traded between $51.150 and $55.990. Currently, there are approximately 96.05 million shares outstanding for CRISPR Therapeutics AG.

CRISPR Therapeutics AG’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

CRISPR Therapeutics AG Stock Price History

CRISPR Therapeutics AG’s (CRSP) price is currently down 7.73% so far this month.

During the month of June, CRISPR Therapeutics AG’s stock price has reached a high of $59.000 and a low of $50.520.

Over the last year, CRISPR Therapeutics AG has hit prices as high as $78.480 and as low as $39.585. Year to date, CRISPR Therapeutics AG’s stock is down 1.14%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused CRISPR Therapeutics AG Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 05, 2026, there were 2 analysts who downgraded CRISPR Therapeutics AG’s stock and 4 analysts who upgraded over the last month.

Additionally, you'll want to evaluate CRISPR Therapeutics AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on CRISPR Therapeutics AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about CRISPR Therapeutics AG (CRSP) by visiting AAII Stock Evaluator.

Relative Price Strength of CRISPR Therapeutics AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 05, 2026, CRISPR Therapeutics AG has a weighted four-quarter relative price strength of -1.04%, which translates to a Momentum Score of 56 and is considered to be Average.

Want to learn more about how CRISPR Therapeutics AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

CRISPR Therapeutics AG Stock Price: Bottom Line

As of June 5, 2026, CRISPR Therapeutics AG’s stock price is $51.840, which is down 8.97% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like CRISPR Therapeutics AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.